Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma

Michael Brada, Sally Stenning, Rhian Gabe, Lindsay C Thompson, David Levy, Roy Rampling, Sara Erridge, Frank Saran, Rao Gattamaneni, Kirsten Hopkins, Sarah Beall, V Peter Collins, Siow-Ming Lee

Research output: Contribution to journalArticlepeer-review


Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG). No prospective comparison with nitrosourea-based chemotherapy exists. We report, to our knowledge, the first randomized trial of procarbazine, lomustine, and vincristine (PCV) versus TMZ in chemotherapy-naive patients with recurrent HGG.
Original languageEnglish
Pages (from-to)4601-1408
Number of pages8
JournalJournal of Clinical Oncology
Issue number30
Publication statusPublished - 20 Oct 2010

Cite this